[{"id":"dddae553-9ce4-4728-9047-032010347ec6","acronym":"","url":"https://clinicaltrials.gov/study/NCT07471776","created_at":"2026-03-28T01:44:37.396Z","updated_at":"2026-03-28T01:44:37.396Z","phase":"Phase 2","brief_title":"Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer","source_id_and_acronym":"NCT07471776","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy) • Datroway (datopotamab deruxtecan-dlnk) • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 03/11/2026","start_date":" 03/11/2026","primary_txt":" Primary completion: 03/11/2028","primary_completion_date":" 03/11/2028","study_txt":" Completion: 03/11/2029","study_completion_date":" 03/11/2029","last_update_posted":"2026-03-13"},{"id":"258815b3-da9e-48e7-8a38-615cfaef4dbd","acronym":"TROPION-Lung02","url":"https://clinicaltrials.gov/study/NCT04526691","created_at":"2021-01-18T21:40:42.295Z","updated_at":"2025-02-25T14:07:50.610Z","phase":"Phase 1","brief_title":"Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)","source_id_and_acronym":"NCT04526691 - TROPION-Lung02","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • KRAS • BRAF • ALK • ROS1 • PD-L2 • NTRK • TACSTD2","pipe":" | ","alterations":" KRAS mutation","tags":["EGFR • KRAS • BRAF • ALK • ROS1 • PD-L2 • NTRK • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 09/15/2020","start_date":" 09/15/2020","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 04/15/2026","study_completion_date":" 04/15/2026","last_update_posted":"2025-02-19"},{"id":"2da5468a-79d4-4eeb-942f-5b05fa2fb4d8","acronym":"CERTIS1","url":"https://clinicaltrials.gov/study/NCT05417594","created_at":"2022-06-14T22:56:26.797Z","updated_at":"2025-02-25T14:08:54.388Z","phase":"Phase 1/2","brief_title":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","source_id_and_acronym":"NCT05417594 - CERTIS1","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • HRD • BRCA • RAD51C • RAD51D","pipe":" | ","alterations":" HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation","tags":["HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • HRD • BRCA • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Enhertu (fam-trastuzumab deruxtecan-nxki) • Datroway (datopotamab deruxtecan-dlnk) • AZD9574"],"overall_status":"Recruiting","enrollment":" Enrollment 490","initiation":"Initiation: 06/24/2022","start_date":" 06/24/2022","primary_txt":" Primary completion: 08/28/2026","primary_completion_date":" 08/28/2026","study_txt":" Completion: 08/28/2026","study_completion_date":" 08/28/2026","last_update_posted":"2025-02-19"},{"id":"57bae4b0-28a5-4fa9-adc4-a7b4d7841588","acronym":"NeoCOAST-2","url":"https://clinicaltrials.gov/study/NCT05061550","created_at":"2021-09-29T11:53:57.404Z","updated_at":"2025-02-25T15:12:20.063Z","phase":"Phase 2","brief_title":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05061550 - NeoCOAST-2","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • Datroway (datopotamab deruxtecan-dlnk) • oleclumab (MEDI9447) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • falbikitug (AZD0171) • monalizumab (IPH2201)"],"overall_status":"Recruiting","enrollment":" Enrollment 630","initiation":"Initiation: 04/14/2022","start_date":" 04/14/2022","primary_txt":" Primary completion: 05/09/2030","primary_completion_date":" 05/09/2030","study_txt":" Completion: 05/09/2030","study_completion_date":" 05/09/2030","last_update_posted":"2025-02-13"},{"id":"9e22f735-9f0d-4c3a-92fb-91f43ae1a4bd","acronym":"TROPION-LUNG01","url":"https://clinicaltrials.gov/study/NCT04656652","created_at":"2021-01-19T20:41:43.327Z","updated_at":"2025-02-25T14:59:32.426Z","phase":"Phase 3","brief_title":"Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)","source_id_and_acronym":"NCT04656652 - TROPION-LUNG01","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • PD-L1 • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET exon 14 mutation","tags":["EGFR • PD-L1 • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 590","initiation":"Initiation: 12/21/2020","start_date":" 12/21/2020","primary_txt":" Primary completion: 05/10/2024","primary_completion_date":" 05/10/2024","study_txt":" Completion: 06/21/2025","study_completion_date":" 06/21/2025","last_update_posted":"2025-02-13"},{"id":"6d363f74-eebb-42b8-8282-8889b9922b4e","acronym":"TROPION-Breast04","url":"https://clinicaltrials.gov/study/NCT06112379","created_at":"2023-11-01T15:12:45.942Z","updated_at":"2025-02-25T16:40:21.913Z","phase":"Phase 3","brief_title":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","source_id_and_acronym":"NCT06112379 - TROPION-Breast04","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride • capecitabine • cyclophosphamide • epirubicin • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Recruiting","enrollment":" Enrollment 1728","initiation":"Initiation: 11/14/2023","start_date":" 11/14/2023","primary_txt":" Primary completion: 03/29/2028","primary_completion_date":" 03/29/2028","study_txt":" Completion: 08/28/2030","study_completion_date":" 08/28/2030","last_update_posted":"2025-02-06"},{"id":"469953ef-24ff-4f0d-8592-38f0c64f71f3","acronym":"TROPION-Lung04","url":"https://clinicaltrials.gov/study/NCT04612751","created_at":"2021-01-19T20:32:55.031Z","updated_at":"2025-02-25T16:45:13.114Z","phase":"Phase 1","brief_title":"Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04612751 - TROPION-Lung04","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)"],"overall_status":"Recruiting","enrollment":" Enrollment 371","initiation":"Initiation: 02/02/2021","start_date":" 02/02/2021","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-05"},{"id":"6cdcc31a-0ce3-49ee-bdf9-1051ddeebebe","acronym":"TROPION-Lung10","url":"https://clinicaltrials.gov/study/NCT06357533","created_at":"2024-04-10T18:42:49.173Z","updated_at":"2025-02-25T16:55:47.733Z","phase":"Phase 3","brief_title":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations","source_id_and_acronym":"NCT06357533 - TROPION-Lung10","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1 • TACSTD2","pipe":" | ","alterations":" TROP2 positive","tags":["PD-L1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TROP2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 675","initiation":"Initiation: 04/11/2024","start_date":" 04/11/2024","primary_txt":" Primary completion: 04/24/2028","primary_completion_date":" 04/24/2028","study_txt":" Completion: 05/24/2030","study_completion_date":" 05/24/2030","last_update_posted":"2025-02-04"},{"id":"2556a800-12ac-4ffc-b124-64c3995bab28","acronym":"AVANZAR","url":"https://clinicaltrials.gov/study/NCT05687266","created_at":"2023-01-18T15:59:54.978Z","updated_at":"2025-02-25T17:31:49.301Z","phase":"Phase 3","brief_title":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","source_id_and_acronym":"NCT05687266 - AVANZAR","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • BRAF • ALK • ROS1 • TACSTD2","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • ROS1 rearrangement","tags":["EGFR • BRAF • ALK • ROS1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • Datroway (datopotamab deruxtecan-dlnk) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1350","initiation":"Initiation: 12/29/2022","start_date":" 12/29/2022","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-01-30"},{"id":"ef68472b-7dd2-408d-a78b-45ffa120bc34","acronym":"Tropion-Lung08","url":"https://clinicaltrials.gov/study/NCT05215340","created_at":"2022-02-05T18:27:45.512Z","updated_at":"2025-02-25T15:00:14.693Z","phase":"Phase 3","brief_title":"Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations","source_id_and_acronym":"NCT05215340 - Tropion-Lung08","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • TACSTD2","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation","tags":["EGFR • PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Recruiting","enrollment":" Enrollment 740","initiation":"Initiation: 03/04/2022","start_date":" 03/04/2022","primary_txt":" Primary completion: 02/29/2028","primary_completion_date":" 02/29/2028","study_txt":" Completion: 04/30/2028","study_completion_date":" 04/30/2028","last_update_posted":"2024-12-13"},{"id":"84d273e3-f912-4f66-80af-054c9469875c","acronym":"TROPION-PanTumor01","url":"https://clinicaltrials.gov/study/NCT03401385","created_at":"2021-01-18T16:47:07.204Z","updated_at":"2025-02-25T14:58:37.689Z","phase":"Phase 1","brief_title":"First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)","source_id_and_acronym":"NCT03401385 - TROPION-PanTumor01","lead_sponsor":"Daiichi Sankyo Co., Ltd.","biomarkers":" HER-2 • ER • PGR • ERBB3 • CD4 • TACSTD2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HER-2 expression","tags":["HER-2 • ER • PGR • ERBB3 • CD4 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 890","initiation":"Initiation: 01/31/2018","start_date":" 01/31/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-12-03"},{"id":"b0b8fd2c-45d2-439d-baa9-7ef0bc159fed","acronym":"TROPION-Lung07","url":"https://clinicaltrials.gov/study/NCT05555732","created_at":"2022-09-27T14:04:32.746Z","updated_at":"2025-02-25T15:00:38.318Z","phase":"Phase 3","brief_title":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","source_id_and_acronym":"NCT05555732 - TROPION-Lung07","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • PD-L1 • BRAF • ALK • RET • ROS1 • TACSTD2","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • BRAF • ALK • RET • ROS1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Datroway (datopotamab deruxtecan-dlnk) • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 1170","initiation":"Initiation: 01/11/2023","start_date":" 01/11/2023","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-11-12"},{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"cc9ebf40-781f-4144-86b4-f2c463366b6e","acronym":"TROPION-Breast05","url":"https://clinicaltrials.gov/study/NCT06103864","created_at":"2023-10-27T17:13:52.697Z","updated_at":"2024-07-02T16:35:00.585Z","phase":"Phase 3","brief_title":"A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer","source_id_and_acronym":"NCT06103864 - TROPION-Breast05","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Recruiting","enrollment":" Enrollment 625","initiation":"Initiation: 11/23/2023","start_date":" 11/23/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 04/23/2029","study_completion_date":" 04/23/2029","last_update_posted":"2024-05-29"},{"id":"84a680b4-a96a-45c2-825f-d8e10004766e","acronym":"BEGONIA","url":"https://clinicaltrials.gov/study/NCT03742102","created_at":"2021-01-18T18:19:46.394Z","updated_at":"2024-07-02T16:35:02.191Z","phase":"Phase 1/2","brief_title":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT03742102 - BEGONIA","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression • PD-L1 expression + HER-2 overexpression","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression • PD-L1 expression + HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • Truqap (capivasertib) • Datroway (datopotamab deruxtecan-dlnk) • oleclumab (MEDI9447)"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 11/14/2024","primary_completion_date":" 11/14/2024","study_txt":" Completion: 11/14/2024","study_completion_date":" 11/14/2024","last_update_posted":"2024-05-21"},{"id":"cacc6ec6-cc9c-4631-96db-9a1cadb66db9","acronym":"TROPION-Breast01","url":"https://clinicaltrials.gov/study/NCT05104866","created_at":"2021-11-03T13:53:11.926Z","updated_at":"2024-07-02T16:35:08.148Z","phase":"Phase 3","brief_title":"A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)","source_id_and_acronym":"NCT05104866 - TROPION-Breast01","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 732","initiation":"Initiation: 10/18/2021","start_date":" 10/18/2021","primary_txt":" Primary completion: 08/15/2025","primary_completion_date":" 08/15/2025","study_txt":" Completion: 08/15/2025","study_completion_date":" 08/15/2025","last_update_posted":"2024-04-23"},{"id":"8f022a9d-6b6c-47b3-b42e-3770069b52cd","acronym":"TROPION-PanTumor02","url":"https://clinicaltrials.gov/study/NCT05460273","created_at":"2022-07-15T16:05:32.169Z","updated_at":"2024-07-02T16:35:09.058Z","phase":"Phase 1/2","brief_title":"A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)","source_id_and_acronym":"NCT05460273 - TROPION-PanTumor02","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • HER-2 • ALK • PGR • ROS1 • TACSTD2","pipe":" | ","alterations":" HER-2 negative • HER-2 expression • PGR negative","tags":["EGFR • HER-2 • ALK • PGR • ROS1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 119","initiation":"Initiation: 07/11/2022","start_date":" 07/11/2022","primary_txt":" Primary completion: 11/07/2023","primary_completion_date":" 11/07/2023","study_txt":" Completion: 05/06/2024","study_completion_date":" 05/06/2024","last_update_posted":"2024-04-17"},{"id":"8c27375e-dbbf-4085-930d-9f071f33e371","acronym":"TROPION-Lung05","url":"https://clinicaltrials.gov/study/NCT04484142","created_at":"2021-01-18T21:31:48.583Z","updated_at":"2025-02-25T14:59:16.191Z","phase":"Phase 2","brief_title":"Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)","source_id_and_acronym":"NCT04484142 - TROPION-Lung05","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • ROS1 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • MET exon 14 mutation","tags":["EGFR • KRAS • BRAF • ALK • MET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 137","initiation":"Initiation: 03/30/2021","start_date":" 03/30/2021","primary_txt":" Primary completion: 03/10/2023","primary_completion_date":" 03/10/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-09"},{"id":"56d3ec14-b4cc-42e0-9846-fa13917833dc","acronym":"TROPION-Breast02","url":"https://clinicaltrials.gov/study/NCT05374512","created_at":"2022-05-16T13:53:41.802Z","updated_at":"2024-07-02T16:35:13.566Z","phase":"Phase 3","brief_title":"A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)","source_id_and_acronym":"NCT05374512 - TROPION-Breast02","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" PD-L1 expression • PD-L1 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 05/16/2022","start_date":" 05/16/2022","primary_txt":" Primary completion: 12/03/2025","primary_completion_date":" 12/03/2025","study_txt":" Completion: 12/03/2025","study_completion_date":" 12/03/2025","last_update_posted":"2024-03-21"},{"id":"c281a94f-ba0b-4b22-9966-de04e9d676d7","acronym":"TUXEDO-2","url":"https://clinicaltrials.gov/study/NCT05866432","created_at":"2023-05-19T13:04:50.730Z","updated_at":"2024-07-02T16:35:32.586Z","phase":"Phase 2","brief_title":"Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases","source_id_and_acronym":"NCT05866432 - TUXEDO-2","lead_sponsor":"Medical University of Vienna","biomarkers":" PD-L1","pipe":" | ","alterations":" HR negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 05/23/2026","primary_completion_date":" 05/23/2026","study_txt":" Completion: 05/23/2026","study_completion_date":" 05/23/2026","last_update_posted":"2023-10-19"},{"id":"30f26824-93d6-4888-bf20-0ab842b64d42","acronym":"ICARUS-LUNG01","url":"https://clinicaltrials.gov/study/NCT04940325","created_at":"2021-06-25T22:54:17.201Z","updated_at":"2024-07-02T16:36:28.657Z","phase":"Phase 2","brief_title":"Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04940325 - ICARUS-LUNG01","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" EGFR • BRAF • ALK • MET • ROS1 • NTRK","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • RET mutation • MET mutation • NTRK fusion","tags":["EGFR • BRAF • ALK • MET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • RET mutation • MET mutation • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/12/2021","start_date":" 05/12/2021","primary_txt":" Primary completion: 11/12/2022","primary_completion_date":" 11/12/2022","study_txt":" Completion: 11/12/2025","study_completion_date":" 11/12/2025","last_update_posted":"2021-06-25"}]